New technologies have shown that in around thirty percent of patients cardiac stents are entirely unnecessary, according to cardiologist Dr Ramesh Babu Pothineni, the managing director of Ramesh Hospitals Group. Cardiac stents have been a matter of contention in recent years in India, primarily due to them being the focal point over the capping of …
Price capping of medical devices has been one of the more controversial measures the government has taken to reduce the cost of healthcare to the patient. The move drew condemnation from hospitals, claiming it would leave considerable holes in profit margins. Criticisms were also levied from the US as a number of US companies such …
Price caps or trade margins, what causes India’s pricing woes? Read More »
India has responded to US criticism of the price capping of medical devices with defiance. It is refusing to abstain from continued price regulation. India received a specific mention in the US Special 301 reports from the National Trade Estimate Report on Foreign Trade Barriers (NTE) regarding the price capping. The report identifies India’s National …
The Indian government’s decision to cap the price mark ups imposed on cardiac stents was feared by some for its potential to cause foreign companies to simply stop marketing their stents in India. These fears appear to have come to fruition as Abbott Healthcare have recently sent requests to the National Pharmaceutical Pricing Authority (NPPA) …
Abbott Healthcare to withdraw cardiac stents from India Read More »
Hospitals and manufacturers are now faced with a reduction in profits margin of up to 85 percent following the price capping of cardiac stents. The price cap has had some unintended consequences. Amongst these are the myriad of ways both hospitals and manufacturers have tried to avoid the losses imposed on them by the cuts. …
Price cap on stents, how hospitals and manufacturers may beat the cap Read More »
Global pharmaceutical companies are trying to withdraw from the Indian coronary stent market following a price cap introduced by the National Pharmaceutical Pricing Authority (NPPA). The price cap of stents has proven an unpopular move amongst international investors and pharmaceutical manufacturers. Some international pharmaceutical companies, such as Abbott and Medtronic have already submitted withdrawal requests …
Stent price caps chasing manufacturers from the market Read More »
The Indian government has declared that within 10-15 days (as of the 18th January) the price of cardiac stents is to be capped. This announcement follows a host of condemnation over the high cost of stents along with the corresponding cardiac operations. Criticism had also been aimed at the fact that Indian-produced stents were costing …
Health Issues India is a web portal that tracks key health stories and issues in India. On our website, you will find a guide to some of the latest trends, research, reports and journals on health. We provide original interviews and opinions of specialists as well as our own commentary on issues and events.
Subscribe our newsletter to stay updated
Copyright © 2023 | Health Issues India | All rights reserved.
